The European Medicines Agency (EMEA) has been formally notified by UCB Pharma S.A. of its decision to withdraw the application for a centralised marketing authorisation for the medicine Lacosamide Pain UCB Pharma (lacosamide) film-coated tablets. Lacosamide Pain UCB Pharma was expected to be used for the treatment of diabetic neuropathic pain in adults.

More: continued here

This entry was posted on Tuesday, September 30th, 2008 at 11:09 pm and is filed under Diabetes. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.